233 related articles for article (PubMed ID: 14647149)
61. Efficient carboplatin single therapy in a mouse model of human testicular nonseminomatous germ cell tumor.
Aharinejad S; Fink M; Abri H; Nedwed S; Schlag MG; Macfelda K; Abraham D; Miksovsky A; Höltl E; Höltl W
J Urol; 2002 Jan; 167(1):368-74. PubMed ID: 11743358
[TBL] [Abstract][Full Text] [Related]
62. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay.
Motzer RJ; Reed E; Perera F; Tang D; Shamkhani H; Poirier MC; Tsai WY; Parker RJ; Bosl GJ
Cancer; 1994 Jun; 73(11):2843-52. PubMed ID: 7514956
[TBL] [Abstract][Full Text] [Related]
63. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
64. Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer.
Hartmann JT; Kuczyk MA; Kollmannsberger C; Kanz L; Bokemeyer C
World J Urol; 1999 Oct; 17(5):324-33. PubMed ID: 10552153
[TBL] [Abstract][Full Text] [Related]
65. Two cycles of cisplatin-based chemotherapy for low-volume retroperitoneal stage II nonseminomatous germ cell tumours.
Steiner H; Müller T; Gozzi C; Akkad T; Bartsch G; Berger AP
BJU Int; 2006 Aug; 98(2):349-52. PubMed ID: 16626306
[TBL] [Abstract][Full Text] [Related]
66. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
Kondagunta GV; Bacik J; Donadio A; Bajorin D; Marion S; Sheinfeld J; Bosl GJ; Motzer RJ
J Clin Oncol; 2005 Sep; 23(27):6549-55. PubMed ID: 16170162
[TBL] [Abstract][Full Text] [Related]
67. Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors.
Tjulandin SA; Garin AM; Mescheryakov AA; Perevodchikova NI; Gorbunova VA; Sokolov AV; Ljubimova NV; Mironova GT; Molchanov GV; Ozols RF
Ann Oncol; 1993 Sep; 4(8):663-7. PubMed ID: 8240996
[TBL] [Abstract][Full Text] [Related]
68. Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours.
Mendoza J; Martínez J; Hernández C; Pérez-Montiel D; Castro C; Fabián-Morales E; Santibáñez M; González-Barrios R; Díaz-Chávez J; Andonegui MA; Reynoso N; Oñate LF; Jiménez MA; Núñez M; Dyer R; Herrera LA
Br J Cancer; 2013 Jul; 109(1):68-75. PubMed ID: 23807173
[TBL] [Abstract][Full Text] [Related]
69. Oncological outcomes of metastatic testicular cancers under centralized management through regional medical network.
Inai H; Kawai K; Kojima T; Joraku A; Shimazui T; Yamauchi A; Miyagawa T; Endo T; Fukuhara Y; Miyazaki J; Uchida K; Nishiyama H
Jpn J Clin Oncol; 2013 Dec; 43(12):1249-54. PubMed ID: 24101656
[TBL] [Abstract][Full Text] [Related]
70. Fertility after chemotherapy for testicular germ cell cancer.
Pont J; Albrecht W
Fertil Steril; 1997 Jul; 68(1):1-5. PubMed ID: 9207575
[TBL] [Abstract][Full Text] [Related]
71. Comparative antitumour activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma xenografts.
Harstrick A; Casper J; Schmoll HJ
Int J Androl; 1987 Feb; 10(1):139-45. PubMed ID: 3034790
[TBL] [Abstract][Full Text] [Related]
72. Effects of hypoxia on human cancer cell line chemosensitivity.
Strese S; Fryknäs M; Larsson R; Gullbo J
BMC Cancer; 2013 Jul; 13():331. PubMed ID: 23829203
[TBL] [Abstract][Full Text] [Related]
73. Salvage chemotherapy in relapsed germ cell tumors.
Beyer J; Rick O; Siegert W; Bokemeyer C
World J Urol; 2001 Apr; 19(2):90-3. PubMed ID: 11374323
[TBL] [Abstract][Full Text] [Related]
74. Identification of genomic changes associated with cisplatin resistance in testicular germ cell tumor cell lines.
Noel EE; Perry J; Chaplin T; Mao X; Cazier JB; Joel SP; Oliver RT; Young BD; Lu YJ
Genes Chromosomes Cancer; 2008 Jul; 47(7):604-13. PubMed ID: 18384131
[TBL] [Abstract][Full Text] [Related]
75. [Treatment of metastatic testicular carcinoma according to prognosis; new development].
de Wit R; Stoter G
Ned Tijdschr Geneeskd; 2001 Jun; 145(25):1194-9. PubMed ID: 11447874
[TBL] [Abstract][Full Text] [Related]
76. Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors.
Schmidtova S; Kalavska K; Kucerova L
Curr Oncol Rep; 2018 Sep; 20(11):88. PubMed ID: 30259297
[TBL] [Abstract][Full Text] [Related]
77. [Testicular malignant tumours. Efficacy of germ cell and sex cord tumours treatment protocol in Poland].
Popadiuk S; Korzon M; Chybicka A; Szmyd K; Dzierzega M; Trelińska J; Kowalczyk JR; Wiśniewska-Slusarz H; Woźniak W; Bilska K; Wachowiak J; Konatkowska B; Wysocki M; Krawczuk-Rybak M; Czauderna P; Szumera M; Sznurkowska K; Renke J
Med Wieku Rozwoj; 2006; 10(3 Pt 1):811-7. PubMed ID: 17317912
[TBL] [Abstract][Full Text] [Related]
78. Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity.
Schaffrath J; Schmoll HJ; Voigt W; Müller LP; Müller-Tidow C; Mueller T
PLoS One; 2017; 12(6):e0178930. PubMed ID: 28591197
[TBL] [Abstract][Full Text] [Related]
79. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
Motzer RJ; Sheinfeld J; Mazumdar M; Bains M; Mariani T; Bacik J; Bajorin D; Bosl GJ
J Clin Oncol; 2000 Jun; 18(12):2413-8. PubMed ID: 10856101
[TBL] [Abstract][Full Text] [Related]
80. Carboplatin in the combination chemotherapy of non-seminomatous germ cell tumours.
Horwich A; Bliss J
Ann Oncol; 1996 Dec; 7(10):989-91. PubMed ID: 9037354
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]